CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Obseva SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Obseva SA
Chemin des Aulx 12
Phone: +41 225521558p:+41 225521558 PLAN-LES-OUATES, 1228  Switzerland Ticker: OBSNOBSN
This company ceased filing statements with the SEC on 4/26/2023.
Filed for Reorganization Proceedings on 1/31/2024
On 1/31/2024, ObsEva SA announced that it was granted a temporary Moratorium (Sursis Provisoire) by the Competent Court in Geneva. The Moratorium limits the ability of ObsEva's creditors to enforce their claims against the Company while it evaluates the possibility of a Restructuring or orderly Liquidation. The Court appointed a Commissioner (commissaire) to supervise the Company's activities during the process. The Moratorium is for a period of four months ending 5/29/2024.
Business Summary
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer & Director ErnestLoumaye,
Interim Chairman of the Board ErnestLoumaye 70 3/13/2023 11/1/2012
Chief Scientific Officer Jean-PierreGotteland
11 additional Officers and Directors records available in full report.

Business Names
Business Name
22D
ObsEva Europe B.V.
ObsEva Ireland Limited
4 additional Business Names available in full report.

General Information
Number of Employees: 15 (As of 12/31/2022)
Outstanding Shares: 117,177,287 (As of 6/30/2023)
Shareholders: 21
Stock Exchange: SWF
Federal Tax Id: 253914856
Email Address: delphine.renaud@obseva.ch


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024